Round 10 Results, by Country
Author:
Bernard Rivers
Article Type:Article Number: 3
ABSTRACT Details are provided of the Board's decision regarding each eligible Round 10 proposal.
Based on advice from the TRP, the Board divided eligible Round 10 proposals into five categories, as follows:
- Category 1: Approved proposals requiring no or minor clarifications; any clarifications need to be provided within eight weeks and then given a final approval by the TRP Chair or Vice-Chair.
- Category 2: Proposals that are approved subject to the required clarifications being provided within a limited timeframe (six weeks for the applicant to provide an initial detailed response to the TRP queries, and a further three months to obtain the final TRP approval should further clarifications be requested). The TRP Chair and Vice-Chair need to give final approval.
- Category 2B: Proposals that are treated as those in Category 2, but are regarded as being relatively weak, on grounds of technical merit and/or issues of feasibility and likelihood of effective implementation.
- Category 3: Proposals not approved in their present form, though applicants are encouraged to resubmit in a future round following major revision.
- Category 4: Proposals that are rejected, with applicants not encouraged to resubmit in any similar form.
The Board approved all proposals in Categories 1, 2 and 2B.
Table 8 provides a summary of the Round 10 results by category. Tables 9 and 10 show the results for each applicant.
Table 8: Round 10 results by category
|
Category |
Number of proposals |
TRP-recommended funding |
|
|
(Years 1-2) |
(Years 1-5) |
||
| Approved: Category 1 |
3 |
$0.05 b. |
$0.14 b. |
| Approved: Category 2 |
49 |
$1.03 b. |
$2.73 b. |
| Approved: Category 2B |
27 |
$0.65 b. |
$1.85 b. |
| Subtotal: All Approved Proposals: |
79 |
$1.73 b. |
$4.72 b. |
| Not Approved: Category 3 |
56 |
$1.64 b. |
$4.21 b. |
| Not Approved: Category 4 |
15 |
$0.78 b. |
$2.22 b. |
| Not Approved: Parts of Category 1, 2 and 2B proposals not recommended for funding * |
n/a |
$0.14 b. |
$0.48 b. |
| Subtotal: All Non-Approved Proposals: |
71 |
$2.56 b. |
$6.91 b. |
| Total: All Proposals |
150 |
$4.30 b. |
$11.63 b. |
* This refers to a situation where a disease proposal with an HSS request attached has been submitted, and the TRP has recommended, and the Board has approved, either the disease proposal or the HSS request, but not both.
Table 9: Round 10 results, by country
Notes:
1. In the following table, DP = disease part.
2. For approved proposals, the costs shown in the last two columns are the amounts recommended by the TRP. For proposals that were not approved, the costs are the amounts requested by the applicant.
|
Applicant |
Disease component |
Applicant type |
Decision |
Cate-gory |
Cost |
||
|
(Years 1-2) |
(Years 1-5) |
||||||
| Afghanistan | TB (DP + HSS part) |
CCM |
Approved |
2 |
€ 16,132,533 |
€ 23,330,719 |
|
| Angola | HIV |
CCM |
Approved |
2B |
$25,877,952 |
$68,884,971 |
|
| Angola | Malaria |
CCM |
Approved |
1 |
$40,435,549 |
$111,239,055 |
|
| Argentina | HIV MARPs |
CCM |
Approved |
2 |
$4,933,812 |
$12,500,000 |
|
| Armenia | HIV MARPs |
CCM |
Not approved |
3 |
€ 2,328,230 |
€ 4,817,816 |
|
| Armenia * | TB (DP) |
CCM |
Approved |
2 |
€ 3,310,881 |
€ 8,881,651 |
|
| Armenia | TB (HSS part) |
CCM |
Not approved |
n/a |
€ 1,180,614 |
€ 2,159,904 |
|
| Azerbaijan | HIV MARPs |
CCM |
Not approved |
3 |
$3,546,724 |
$12,466,986 |
|
| Azerbaijan | Malaria |
CCM |
Not approved |
3 |
€ 1,880,538 |
€ 3,571,100 |
|
| Bangladesh ** | TB |
CCM |
Approved |
2B |
$11,677,496 |
$98,543,757 |
|
| Belize | HIV MARPs |
CCM |
Not approved |
3 |
$2,602,746 |
$6,722,026 |
|
| Belize | TB |
CCM |
Not approved |
4 |
$2,823,065 |
$5,960,681 |
|
| Benin | HIV |
CCM |
Not approved |
3 |
€ 11,286,254 |
€ 21,692,352 |
|
| Benin | TB |
CCM |
Not approved |
3 |
€ 993,858 |
€ 2,274,009 |
|
| Bosnia & Herz. | HIV |
CCM |
Not approved |
4 |
€ 2,800,310 |
€ 5,497,810 |
|
| Botswana | HIV |
CCM |
Not approved |
3 |
$47,926,893 |
$137,642,491 |
|
| Botswana | TB |
CCM |
Not approved |
3 |
$10,828,604 |
$25,258,210 |
|
| Brazil | HIV MARPs |
CCM |
Not approved |
3 |
$5,000,000 |
$12,500,000 |
|
| Burkina Faso | HIV (DP) |
CCM |
Approved |
2B |
€ 38,993,903 |
€ 97,448,392 |
|
| Burkina Faso | HIV (HSS part) |
CCM |
Not approved |
n/a |
€ 10,272,650 |
€ 24,384,963 |
|
| Burundi | TB |
CCM |
Not approved |
3 |
$4,830,351 |
$13,212,893 |
|
| Cambodia | HIV |
CCM |
Not approved |
3 |
$23,124,597 |
$47,452,279 |
|
| Cambodia | TB (DP + HSS part) |
CCM |
Not approved |
3 |
$47,313,760 |
$132,570,309 |
|
| Cameroon | HIV |
CCM |
Approved |
2B |
€ 30,200,540 |
€ 97,411,942 |
|
| Cape Verde | Malaria |
CCM |
Approved |
2B |
€ 968,724 |
€ 1,414,366 |
|
| Central Af. Rep. | HIV (DP + HSS part) |
CCM |
Not approved |
3 |
€ 29,077,778 |
€ 64,570,395 |
|
| Chad | HIV |
CCM |
Not approved |
3 |
€ 31,801,787 |
€ 94,985,597 |
|
| Chad | TB (DP + HSS part) |
CCM |
Not approved |
3 |
€ 11,599,749 |
€ 22,450,241 |
|
| China | Malaria |
CCM |
Approved |
2B |
$5,830,102 |
$15,704,363 |
|
| Colombia | TB |
CCM |
Approved |
2B |
$5,390,584 |
$11,271,656 |
|
| Congo Rep. | HIV |
CCM |
Not approved |
3 |
€ 4,674,974 |
€ 9,978,943 |
|
| Congo DR | HIV |
CCM |
Not approved |
3 |
$111,533,674 |
$295,297,357 |
|
| Congo DR | Malaria |
CCM |
Approved |
2 |
$73,922,870 |
$185,122,386 |
|
| Cote d’Ivoire | HIV (DP + HSS part) |
CCM |
Not approved |
3 |
€ 57,632,004 |
€ 133,432,755 |
|
| Djibouti | TB |
CCM |
Approved |
2 |
€ 2,461,552 |
€ 6,080,117 |
|
| Dominican Rep. | HIV MARPs |
CCM |
Not approved |
4 |
$4,950,940 |
$12,496,996 |
|
| Eritrea * | HIV (DP + HSS part) |
CCM |
Approved |
2 |
$20,818,140 |
$59,897,311 |
|
| Eritrea * ** | TB |
CCM |
Approved |
2B |
$7,316,801 |
$22,815,431 |
|
| Ethiopia | HIV |
CCM |
Not approved |
3 |
$88,149,150 |
$176,458,326 |
|
| Ethiopia | Malaria (DP + HSS part) |
CCM |
Not approved |
3 |
$97,848,890 |
$245,989,480 |
|
| Ethiopia | TB |
CCM |
Not approved |
3 |
$21,107,334 |
$82,169,387 |
|
| Georgia | HIV MARPs |
CCM |
Approved |
2 |
€ 3,105,210 |
€ 8,860,077 |
|
| Georgia | TB |
CCM |
Approved |
2 |
€ 7,695,603 |
€ 21,727,729 |
|
| Ghana | HIV (DP + HSS part) |
CCM |
Not approved |
4 |
$499,428,723 |
$1,420,138,447 |
|
| Ghana * | TB |
CCM |
Approved |
2B |
$31,897,744 |
$77,418,445 |
|
| Guinea | HIV (DP + HSS part) |
CCM |
Approved |
2B |
$20,877,516 |
$56,875,437 |
|
| Guinea | Malaria |
CCM |
Approved |
2B |
$32,046,938 |
$46,625,648 |
|
| Guinea Bissau | HIV (DP + HSS part) |
CCM |
Not approved |
3 |
€ 26,167,631 |
€ 63,815,647 |
|
| Guyana | TB |
CCM |
Not approved |
4 |
$486,607 |
$1,050,801 |
|
| Honduras | TB |
CCM |
Approved |
2B |
$6,030,951 |
$12,402,425 |
|
| India | HIV |
CCM |
Not approved |
3 |
$21,412,956 |
$61,404,090 |
|
| Indonesia | TB (DP + HSS part) |
CCM |
Approved |
2 |
$47,727,271 |
$157,544,680 |
|
| Iran | Malaria |
CCM |
Approved |
2 |
$9,363,548 |
$19,578,464 |
|
| Jordan | TB |
CCM |
Approved |
2 |
$2,078,829 |
$4,666,284 |
|
| Kazakhstan | HIV MARPs |
CCM |
Approved |
2 |
$2,404,755 |
$12,449,062 |
|
| Kenya | HIV |
CCM |
Approved |
2B |
$93,376,285 |
$345,103,871 |
|
| Kenya | Malaria |
CCM |
Approved |
2 |
$49,979,579 |
$138,370,324 |
|
| Kyrgyz Rep. | HIV |
CCM |
Approved |
2 |
$11,207,840 |
$41,480,486 |
|
| Kyrgyz Rep. | TB |
CCM |
Not approved |
3 |
$3,842,777 |
$5,659,777 |
|
| Lao PDR | TB (HSS part) |
CCM |
Not approved |
n/a |
$8,155,754 |
$17,158,018 |
|
| Lao PDR ** | TB (DP) |
CCM |
Approved |
2 |
$3,255,999 |
$12,887,910 |
|
| Lesotho | HIV |
CCM |
Not approved |
3 |
$29,594,699 |
$65,273,286 |
|
| Liberia | Malaria (DP + HSS part) |
CCM |
Approved |
2 |
$28,698,063 |
$68,892,692 |
|
| Liberia | TB |
CCM |
Approved |
2B |
$2,862,226 |
$16,061,899 |
|
| Macedonia | HIV MARPs |
CCM |
Approved |
1 |
€ 2,825,259 |
€ 9,407,934 |
|
| Macedonia | TB |
CCM |
Approved |
2 |
€ 2,901,528 |
€ 6,112,713 |
|
| Madagascar | HIV (DP + HSS part) |
CCM |
Not approved |
3 |
$46,050,649 |
$110,739,971 |
|
| Malawi | HIV |
CCM |
Not approved |
3 |
$164,254,176 |
$561,450,164 |
|
| Malaysia | HIV MARPs |
CCM |
Approved |
2B |
$4,672,630 |
$12,405,288 |
|
| Maldives | HIV MARPs |
CCM |
Not approved |
3 |
$2,880,814 |
$8,044,746 |
|
| Mali | Malaria |
CCM |
Approved |
2B |
€ 24,827,735 |
€ 94,873,243 |
|
| Mali | TB |
CCM |
Approved |
2 |
€ 8,053,957 |
€ 13,773,341 |
|
| Mauritius | HIV MARPs |
CCM |
Not approved |
3 |
$2,870,148 |
$12,435,364 |
|
| Moldova | HIV MARPs |
CCM |
Not approved |
3 |
$3,849,298 |
$12,491,713 |
|
| Mongolia | HIV |
CCM |
Not approved |
4 |
$2,218,185 |
$7,248,739 |
|
| Mongolia ** | TB (DP + HSS part) |
CCM |
Approved |
2 |
$3,696,354 |
$9,052,049 |
|
| Morocco | HIV |
CCM |
Approved |
2 |
$14,672,516 |
$43,597,649 |
|
| Morocco | TB |
CCM |
Approved |
2 |
$5,014,439 |
$10,795,334 |
|
| Mozambique | HIV |
CCM |
Not approved |
3 |
$54,163,105 |
$131,214,912 |
|
| Mozambique | TB |
CCM |
Not approved |
3 |
$25,407,092 |
$69,822,783 |
|
| Namibia | HIV |
CCM |
Not approved |
4 |
$15,248,614 |
$44,292,453 |
|
| Namibia | TB |
CCM |
Approved |
2 |
$12,524,672 |
$32,994,241 |
|
| Nepal | HIV |
CCM |
Approved |
2 |
$16,150,553 |
$57,273,249 |
|
| Nicaragua | TB |
CCM |
Not approved |
3 |
$4,106,578 |
$8,247,665 |
|
| Niger | HIV |
CCM |
Not approved |
3 |
€ 30,335,989 |
€ 73,945,907 |
|
| Niger | Malaria |
CCM |
Not approved |
3 |
€ 72,627,052 |
€ 130,641,962 |
|
| Niger | TB (DP + HSS part) |
CCM |
Approved |
2B |
€ 19,035,383 |
€ 42,226,096 |
|
| Nigeria | HIV (DP + HSS part) |
CCM |
Not approved |
4 |
$97,491,288 |
$383,708,645 |
|
| Pakistan * | Malaria (DP) |
CCM |
Approved |
2B |
$23,395,667 |
$51,516,709 |
|
| Pakistan | Malaria (HSS part) |
CCM |
Not approved |
n/a |
$15,199,740 |
$21,594,900 |
|
| Panama | HIV MARPs |
CCM |
Approved |
2 |
$4,202,744 |
$10,273,513 |
|
| Papua NG * | HIV (DP + HSS part) |
CCM |
Approved |
2 |
$23,419,727 |
$46,697,052 |
|
| Peru | HIV MARPs |
CCM |
Approved |
2 |
$4,999,999 |
$12,499,997 |
|
| Peru | Malaria |
CCM |
Not approved |
3 |
$2,835,863 |
$7,741,937 |
|
| Peru | TB |
CCM |
Not approved |
3 |
$15,481,203 |
$29,837,075 |
|
| Russian Fed. | TB |
CCM |
Approved |
2B |
$63,472,958 |
$126,926,245 |
|
| Russian Fed. | TB | Sub-CCM | Not approved |
4 |
€ 20,170,145 |
€ 36,360,264 |
|
| Sao Tome & P. | HIV |
CCM |
Approved |
2 |
$1,279,852 |
$2,476,713 |
|
| Senegal | Malaria |
CCM |
Approved |
2 |
€ 21,650,781 |
€ 62,865,723 |
|
| Senegal * ** | TB |
CCM |
Approved |
2 |
€ 6,335,035 |
€ 17,460,725 |
|
| Sierra Leone | Malaria |
CCM |
Approved |
2 |
$23,255,609 |
$62,649,856 |
|
| Sierra Leone | TB (DP + HSS part) |
CCM |
Not approved |
3 |
$34,333,373 |
$77,234,629 |
|
| Somalia | Malaria (DP + HSS part) | Non-CCM | Approved |
2 |
$39,333,002 |
$84,550,325 |
|
| Somalia * ** | TB | Non-CCM | Approved |
2B |
$14,213,393 |
$58,380,928 |
|
| South Africa | HIV |
CCM |
Approved |
2 |
$128,481,275 |
$302,717,719 |
|
| Sri Lanka | TB (DP + HSS part) |
CCM |
Not approved |
3 |
$11,845,852 |
$25,088,859 |
|
| Sudan North | HIV |
CCM |
Approved |
2 |
$21,944,538 |
$61,919,606 |
|
| Sudan North | Malaria |
CCM |
Approved |
2B |
$61,256,082 |
$182,841,841 |
|
| Sudan South | HIV | Sub-CCM | Not approved |
4 |
$65,528,320 |
$135,697,425 |
|
| Sudan South | Malaria | Sub-CCM | Approved |
2 |
$26,486,653 |
$98,618,453 |
|
| Sudan South | TB | Sub-CCM | Not approved |
3 |
$16,374,061 |
$50,114,047 |
|
| Swaziland | HIV |
CCM |
Not approved |
3 |
$34,723,593 |
$89,609,304 |
|
| Swaziland ** | TB |
CCM |
Approved |
2 |
$11,202,195 |
$39,004,228 |
|
| Syria * | HIV MARPs |
CCM |
Approved |
2B |
$1,723,169 |
$3,396,722 |
|
| Tajikistan | HIV |
CCM |
Not approved |
3 |
$20,521,257 |
$64,745,498 |
|
| Tajikistan | TB |
CCM |
Not approved |
3 |
$49,913,253 |
$115,418,678 |
|
| Tanzania | HIV |
CCM |
Not approved |
3 |
$50,880,157 |
$113,178,230 |
|
| Tanzania | TB |
CCM |
Not approved |
3 |
$33,201,781 |
$68,786,103 |
|
| Thailand | HIV |
CCM |
Approved |
2 |
$15,398,249 |
$42,088,572 |
|
| Thailand * | Malaria |
CCM |
Approved |
2B |
$32,500,432 |
$78,378,690 |
|
| Thailand | TB |
CCM |
Approved |
2 |
$12,344,773 |
$31,716,829 |
|
| Timor-Leste | HIV |
CCM |
Approved |
1 |
$6,798,682 |
$14,254,688 |
|
| Timor-Leste * | Malaria |
CCM |
Approved |
2B |
$7,170,680 |
$22,349,915 |
|
| Timor-Leste | TB |
CCM |
Not approved |
3 |
$2,706,769 |
$9,661,901 |
|
| Togo | HIV |
CCM |
Not approved |
3 |
€ 6,280,885 |
€ 16,083,684 |
|
| Tunisia | HIV MARPs |
CCM |
Not approved |
3 |
$4,144,950 |
$12,499,365 |
|
| Uganda | HIV (DP) |
CCM |
Not approved |
n/a |
$55,834,292 |
$217,300,859 |
|
| Uganda | HIV (HSS part) |
CCM |
Approved |
2 |
$17,917,965 |
$25,251,193 |
|
| Uganda | Malaria |
CCM |
Approved |
2 |
$53,167,057 |
$155,963,673 |
|
| Uganda | TB |
CCM |
Approved |
2 |
$10,391,585 |
$24,757,129 |
|
| Ukraine | HIV |
CCM |
Approved |
2 |
$95,842,099 |
$305,535,421 |
|
| Uruguay | HIV MARPs |
CCM |
Approved |
2 |
$3,953,375 |
$9,572,417 |
|
| Uzbekistan | HIV |
CCM |
Approved |
2 |
$9,519,645 |
$14,828,347 |
|
| Vietnam | HIV (DP) |
CCM |
Not approved |
n/a |
$45,071,739 |
$188,864,423 |
|
| Vietnam | HIV (HSS part) |
CCM |
Approved |
2B |
$42,102,165 |
$86,636,150 |
|
| Yemen | HIV (DP + HSS part) |
CCM |
Not approved |
3 |
$14,565,766 |
$32,312,943 |
|
| Zambia * | HIV |
CCM |
Approved |
2 |
$102,851,986 |
$259,216,608 |
|
| Zanzibar (Tanz.) | TB |
CCM |
Approved |
2 |
$2,633,434 |
$5,912,925 |
|
| Zimbabwe | HIV (DP + HSS part) |
CCM |
Not approved |
3 |
$118,402,303 |
$342,054,472 |
|
| Zimbabwe | Malaria |
CCM |
Approved |
2 |
$14,550,666 |
$24,960,569 |
|
| Zimbabwe | TB |
CCM |
Not approved |
3 |
$12,193,205 |
$25,507,117 |
|
|
Total – 135 country-based proposals |
|||||||
* The TRP-recommended funding has been reduced from the requested amount because the TRP removed certain elements from the proposal.
** These are consolidated proposals. The TRP-recommended funding has been reduced to remove amounts included in the proposals for existing, already funded programmes.
Table 10: Round 10 results for regional applicants
Note: For approved proposals, the costs shown in the last two columns are the amounts recommended by the TRP. For proposals that were not approved, the costs are the amounts requested by the applicant.
|
Applicant |
Disease component |
Applicant type |
Decision |
Cate-gory |
Cost |
|
|
Years 1-2 |
Years 1-5 |
|||||
| AMREF (Re Burundi, Ethiopia, Kenya, Tanzania, Uganda) | TB |
RO |
Not approved |
4 |
$29,868,200 |
$63,996,437 |
| APN+ (Re Bangladesh, Indonesia, Lao PDR, Nepal, Pakistan, Philippines, Viet Nam) * | HIV |
RO |
Approved |
2 |
$1,200,000 |
$3,000,000 |
| ASICAL (Re Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Paraguay, Peru, Uruguay) | HIV MARPs |
RO |
Not approved |
3 |
$4,827,281 |
$11,149,346 |
| CONGA (Re Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama) | HIV MARPs |
RO |
Not approved |
4 |
$4,506,212 |
$12,451,594 |
| ECSA (Re Zambia, Zimbabwe) | TB |
RO |
Not approved |
3 |
$3,322,054 |
$14,593,861 |
| GLIA (Re Burundi, Congo DR, Kenya, Rwanda, Tanzania, Uganda) | HIV MARPs |
RO |
Not approved |
4 |
$4,873,647 |
$12,499,735 |
| HIVOS-SA (Re Lesotho, Mauritius, Namibia, South Africa, Swaziland) | HIV |
RO |
Not approved |
4 |
$12,130,614 |
$36,066,771 |
| ISEAN-HIVOS (Re Indonesia, Malaysia, Philippines, Timor-Leste) | HIV MARPs |
RO |
Approved |
2B |
$4,767,802 |
$12,473,395 |
| MENAHRA (Re Afghanistan, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Morocco, Oman, West Bank and Gaza, Pakistan, Syria, Tunisia) * | HIV MARPs |
RO |
Approved |
2B |
$3,209,492 |
$8,352,698 |
| Meso (Re Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama) | HIV |
RCM |
Not approved |
3 |
$7,868,536 |
$23,214,775 |
| MOZIZA (Re Mozambique, South Africa, Zimbabwe) | Malaria |
RCM |
Not approved |
4 |
$12,322,727 |
$28,043,158 |
| OECS (Re Antigua and Barbuda, Dominica, Grenada, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and Grenadines) | HIV |
RCM |
Not approved |
3 |
$3,112,877 |
$9,059,745 |
| REDCA+ (Re Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama) ** | HIV |
RO |
Approved |
2 |
$2,366,057 |
$9,229,855 |
| REDLACTRANS (Re Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay) | HIV MARPs |
RO |
Not approved |
3 |
$4,994,209 |
$12,500,000 |
| REDTRASEX (Re Argentina, Bolivia, Brazil, Chile, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay) | HIV MARPs |
RO |
Approved |
2 |
$4,328,974 |
$12,496,279 |
|
Total – 15 regional proposals |
||||||
RO = Regional organisation RCM = Regional coordinating mechanism
* The TRP-recommended funding has been reduced from the requested amount because the TRP removed certain elements from the proposal.
** This is a consolidated proposal. The TRP-recommended funding has been reduced to remove amounts included in the proposal for existing, already funded programmes.
